Cargando…

Simultaneous Multi-Antibody Staining in Non-Small Cell Lung Cancer Strengthens Diagnostic Accuracy Especially in Small Tissue Samples

Histological subclassification of non-small cell lung cancer (NSCLC) has growing therapeutic impact. In advanced cancer stages tissue specimens are usually bioptically collected. These small samples are of extraordinary value since molecular analyses are gaining importance for targeted therapies. We...

Descripción completa

Detalles Bibliográficos
Autores principales: Kayser, Gian, Csanadi, Agnes, Otto, Claudia, Plönes, Till, Bittermann, Nicola, Rawluk, Justyna, Passlick, Bernward, Werner, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3572034/
https://www.ncbi.nlm.nih.gov/pubmed/23418554
http://dx.doi.org/10.1371/journal.pone.0056333
_version_ 1782259259954692096
author Kayser, Gian
Csanadi, Agnes
Otto, Claudia
Plönes, Till
Bittermann, Nicola
Rawluk, Justyna
Passlick, Bernward
Werner, Martin
author_facet Kayser, Gian
Csanadi, Agnes
Otto, Claudia
Plönes, Till
Bittermann, Nicola
Rawluk, Justyna
Passlick, Bernward
Werner, Martin
author_sort Kayser, Gian
collection PubMed
description Histological subclassification of non-small cell lung cancer (NSCLC) has growing therapeutic impact. In advanced cancer stages tissue specimens are usually bioptically collected. These small samples are of extraordinary value since molecular analyses are gaining importance for targeted therapies. We therefore studied the feasibility, diagnostic accuracy, economic and prognostic effects of a tissue sparing simultaneous multi-antibody assay for subclassification of NSCLC. Of 265 NSCLC patients tissue multi arrays (TMA) were constructed to simulate biopsy samples. TMAs were stained by a simultaneous bi-color multi-antibody assay consisting of TTF1, Vimentin, p63 and neuroendocrine markers (CD56, chromogranin A, synaptophysin). Classification was based mainly on the current proposal of the IASLC with a hierarchical decision tree for subclassification into adenocarcinoma (LAC), squamous cell carcinoma (SCC), large cell neuroendocrine carcinoma (LCNEC) and NSCLC not otherwise specified. Investigation of tumor heterogeneity showed an explicit lower variation for immunohistochemical analyses compared to conventional classification. Furthermore, survival analysis of our combined immunohistochemical classification revealed distinct separation of each entity's survival curve. This was statistically significant for therapeutically important subgroups (p = 0.045). As morphological and molecular cancer testing is emerging, our multi-antibody assay in combination with standardized classification delivers accurate and reliable separation of histomorphological diagnoses. Additionally, it permits clinically relevant subtyping of NSCLC including LCNEC. Our multi-antibody assay may therefore be of special value, especially in diagnosing small biopsies. It futher delivers substantial prognostic information with therapeutic consequences. Integration of immunohistochemical subtyping including investigation of neuroendocrine differentiation into standard histopathological classification of NSCLC must, therefore, be considered.
format Online
Article
Text
id pubmed-3572034
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-35720342013-02-15 Simultaneous Multi-Antibody Staining in Non-Small Cell Lung Cancer Strengthens Diagnostic Accuracy Especially in Small Tissue Samples Kayser, Gian Csanadi, Agnes Otto, Claudia Plönes, Till Bittermann, Nicola Rawluk, Justyna Passlick, Bernward Werner, Martin PLoS One Research Article Histological subclassification of non-small cell lung cancer (NSCLC) has growing therapeutic impact. In advanced cancer stages tissue specimens are usually bioptically collected. These small samples are of extraordinary value since molecular analyses are gaining importance for targeted therapies. We therefore studied the feasibility, diagnostic accuracy, economic and prognostic effects of a tissue sparing simultaneous multi-antibody assay for subclassification of NSCLC. Of 265 NSCLC patients tissue multi arrays (TMA) were constructed to simulate biopsy samples. TMAs were stained by a simultaneous bi-color multi-antibody assay consisting of TTF1, Vimentin, p63 and neuroendocrine markers (CD56, chromogranin A, synaptophysin). Classification was based mainly on the current proposal of the IASLC with a hierarchical decision tree for subclassification into adenocarcinoma (LAC), squamous cell carcinoma (SCC), large cell neuroendocrine carcinoma (LCNEC) and NSCLC not otherwise specified. Investigation of tumor heterogeneity showed an explicit lower variation for immunohistochemical analyses compared to conventional classification. Furthermore, survival analysis of our combined immunohistochemical classification revealed distinct separation of each entity's survival curve. This was statistically significant for therapeutically important subgroups (p = 0.045). As morphological and molecular cancer testing is emerging, our multi-antibody assay in combination with standardized classification delivers accurate and reliable separation of histomorphological diagnoses. Additionally, it permits clinically relevant subtyping of NSCLC including LCNEC. Our multi-antibody assay may therefore be of special value, especially in diagnosing small biopsies. It futher delivers substantial prognostic information with therapeutic consequences. Integration of immunohistochemical subtyping including investigation of neuroendocrine differentiation into standard histopathological classification of NSCLC must, therefore, be considered. Public Library of Science 2013-02-13 /pmc/articles/PMC3572034/ /pubmed/23418554 http://dx.doi.org/10.1371/journal.pone.0056333 Text en © 2013 Kayser et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Kayser, Gian
Csanadi, Agnes
Otto, Claudia
Plönes, Till
Bittermann, Nicola
Rawluk, Justyna
Passlick, Bernward
Werner, Martin
Simultaneous Multi-Antibody Staining in Non-Small Cell Lung Cancer Strengthens Diagnostic Accuracy Especially in Small Tissue Samples
title Simultaneous Multi-Antibody Staining in Non-Small Cell Lung Cancer Strengthens Diagnostic Accuracy Especially in Small Tissue Samples
title_full Simultaneous Multi-Antibody Staining in Non-Small Cell Lung Cancer Strengthens Diagnostic Accuracy Especially in Small Tissue Samples
title_fullStr Simultaneous Multi-Antibody Staining in Non-Small Cell Lung Cancer Strengthens Diagnostic Accuracy Especially in Small Tissue Samples
title_full_unstemmed Simultaneous Multi-Antibody Staining in Non-Small Cell Lung Cancer Strengthens Diagnostic Accuracy Especially in Small Tissue Samples
title_short Simultaneous Multi-Antibody Staining in Non-Small Cell Lung Cancer Strengthens Diagnostic Accuracy Especially in Small Tissue Samples
title_sort simultaneous multi-antibody staining in non-small cell lung cancer strengthens diagnostic accuracy especially in small tissue samples
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3572034/
https://www.ncbi.nlm.nih.gov/pubmed/23418554
http://dx.doi.org/10.1371/journal.pone.0056333
work_keys_str_mv AT kaysergian simultaneousmultiantibodystaininginnonsmallcelllungcancerstrengthensdiagnosticaccuracyespeciallyinsmalltissuesamples
AT csanadiagnes simultaneousmultiantibodystaininginnonsmallcelllungcancerstrengthensdiagnosticaccuracyespeciallyinsmalltissuesamples
AT ottoclaudia simultaneousmultiantibodystaininginnonsmallcelllungcancerstrengthensdiagnosticaccuracyespeciallyinsmalltissuesamples
AT plonestill simultaneousmultiantibodystaininginnonsmallcelllungcancerstrengthensdiagnosticaccuracyespeciallyinsmalltissuesamples
AT bittermannnicola simultaneousmultiantibodystaininginnonsmallcelllungcancerstrengthensdiagnosticaccuracyespeciallyinsmalltissuesamples
AT rawlukjustyna simultaneousmultiantibodystaininginnonsmallcelllungcancerstrengthensdiagnosticaccuracyespeciallyinsmalltissuesamples
AT passlickbernward simultaneousmultiantibodystaininginnonsmallcelllungcancerstrengthensdiagnosticaccuracyespeciallyinsmalltissuesamples
AT wernermartin simultaneousmultiantibodystaininginnonsmallcelllungcancerstrengthensdiagnosticaccuracyespeciallyinsmalltissuesamples